TVP-1012 1mg

DRUG3 trials

Sponsors

Takeda

Conditions

Parkinson's Disease

Phase 2

A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants

CompletedNCT02337738

TakedaParkinson's Disease

Start: 2015-01-27End: 2016-09-17Updated: 2022-03-02

Phase 3

A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants

CompletedNCT02337751

TakedaParkinson's Disease

Start: 2015-07-10End: 2017-03-14Updated: 2022-03-02

A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants

CompletedNCT02337764

TakedaParkinson's Disease

Start: 2015-02-03End: 2016-09-29Updated: 2022-03-02

Related Papers

Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in Japan

PLoS ONE2022-01-257 citations

Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson's disease.

2019-01-2810 citations